Damià Tormo
Chief Executive Officer @ Artax Biopharma
Valencia, Spain
Damià Tormo is a seed investor at Artax Biopharma in Valencia focused on Biotechnology and Medical. Dr. Tormo has been co-founder and advisor for several biotech companies. Among these companies, he co-founded and was CEO of Bioncotech Therapeutics, a spin-off from the Spanish National Cancer Research Center (CNIO), Restaura Biotech SL (a Polytechnic University of Valencia spin-off), Frozen Shard SL and Polymer Therapeutic Solutions SL. He isalso co-founder and partner of Biocapital Advisors SL.Dr. Tormo holds a BSc from the University of Valencia, Spain, a PhD in Immunology and Molecular Genetics from the University of Bonn, Germany, and a master’s degree in biotechnology management (MBM) from IE Business School, Madrid. He was a post-doc fellow at the University of Michigan. Additionally, he has extensive scientific experience endorsed by scientific publications in prestigious journals. He has recieved scholarships and different awards related to innovation and entrepreneurship such as MIT’s TR35 Spain 2011, Emprendedores sXXI from La Caixa and the Biogen-Idec Foundation award.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 56%
Last updated:
For AI agents: llms.txt
Industries Damià Tormo invests in
Stages Damià Tormo invests in
Countries Damià Tormo invests in
Investment Focus
Industry
- Biotechnology 5 (56%)
- Medical 2 (22%)
- Genetics 2 (22%)
- Health Care 2 (22%)
- Apps 1 (11%)
Stage
- Seed 2 (22%)
- Series B 1 (11%)
- Series C 1 (11%)
- Series D 1 (11%)
- Funding Round 1 (11%)
Country
- Spain 3 (33%)
- Switzerland 1 (11%)
- United States 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Visium
|
Visium is a consulting company specialized in artificial intelligence, machine learning, and consulting. It delivers value to companies at every level of AI development, whether they are just entering the field or have a solid data science department. The company was founded in 2018 and headquartered in Zurich, Switzerland. | May 20, 2026 | |
Integra Therapeutics
|
Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases. | $12.6M / Seed / Sep 08, 2025 | |
Tolerance Bio
|
Tolerance Bio is a biopharmaceutical company focused on manipulating immune tolerance via the thymus to address various immune-mediated diseases thymus. | $20.2M / Seed / Oct 15, 2024 | |
Artax Biopharma
|
Artax Biopharma is a development-stage biopharmaceutical company that is dedicated to the development of new therapies for autoimmune and inflammatory diseases. Its technology provides the compounds with the potential to become first-in-class immunomodulators for the treatment of a wide range of autoimmune and inflammatory diseases.The companywas founded in 2013 and is headquartered in Cambridge, Massachusetts. | $8M / Convertible Note / Aug 06, 2024 | |
Minoryx Therapeutics
|
Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promisingapproach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects. | $54.7M / Series C / May 31, 2022 | |
|
Artax Biopharma
|
Artax Biopharma is a development-stage biopharmaceutical company that is dedicated to the development of new therapies for autoimmune and inflammatory diseases. Its technology provides the compounds with the potential to become first-in-class immunomodulators for the treatment of a wide range of autoimmune and inflammatory diseases.The companywas founded in 2013 and is headquartered in Cambridge, Massachusetts. | $26M / Venture - Series Unknown / May 11, 2022 | |
|
Integra Therapeutics
|
Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases. | $1.7M / Seed / Mar 29, 2022 | |
|
Artax Biopharma
|
Artax Biopharma is a development-stage biopharmaceutical company that is dedicated to the development of new therapies for autoimmune and inflammatory diseases. Its technology provides the compounds with the potential to become first-in-class immunomodulators for the treatment of a wide range of autoimmune and inflammatory diseases.The companywas founded in 2013 and is headquartered in Cambridge, Massachusetts. | Series B / Jun 04, 2020 | |
SANIFIT
|
SANIFIT is a biotechnology company focused on treatments for calcification disorders. | $60.6M / Series D / Jun 26, 2019 |
Co-Investors
About Artax Biopharma
Artax Biopharma is a development-stage biopharmaceutical company that is dedicated to the development of new therapies for autoimmune and inflammatory diseases. Its technology provides the compounds with the potential to become first-in-class immunomodulators for the treatment of a wide range of autoimmune and inflammatory diseases.The companywas founded in 2013 and is headquartered in Cambridge, Massachusetts.
Artax Biopharma Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Damià Tormo
Chief Executive Officer
|
|||
Javier García
Business Development
|
|||
Joseph Lobacki
Chief Executive Officer
|
|||
Thomas McGauley
Chief Financial Officer
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Damià Tormo invest in?
Damià Tormo invests primarily in Biotechnology, Medical and Genetics startups, most often at Seed and Series B stage. Most of the 9 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Damià Tormo last invest?
The most recent investment recorded for Damià Tormo closed in May 2026. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
